CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease

Brain

Volumn 127, Issue 8, 2004, Pages 1748-1754

  Narayan, Srinivas B ^a   Pastor, Johanne V ^a   Mitchison, Hannah M ^b   Bennett, Michael J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Batten disease; Cln3 gene; CLN3 protein; cln3 mice; Neurodegenerative disease

Indexed keywords

ANTIBODY; BATTEN DISEASE PROTEIN; BRAIN PROTEIN; CLN3 LIKE PROTEIN; CLN3 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; MOLECULAR WEIGHT; MOUSE; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION; WILD TYPE;

EID: 4043058035     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh195     Document Type: Article

References (26)

1. Boriack RL, Bennett MJ. CLN-3 protein is expressed in the pancreatic somatostatin-secreting delta cells. Eur J Paediatr Neurol 2001; 5 Suppl A: 99-102.
2. Bronson RT, Donahue LR, Johnson KR, Tanner A, Lane PW, Faust JR. Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am J Med Genet 1998; 77: 289-97.
3. Cooper JD, Messer A, Feng AK, Chua-Couzens J, Mobley WC. Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin like growth factor-1 treatment. J Neurosci 1999; 19: 2556-67.
4. Δ7/8 knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum Mol Genet 2002; 11: 2709-721.
5. Dawson G, Cho S. Batten's disease: clues to neuronal protein catabolism in lysosomes. J Neurosci Res 2000; 60: 133-40.
6. Golabek AA, Kaczmarski W, Kida E, Kaczmarski A, Michalewski MP, Wisniewski KE. Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in mammalian cells in vitro. Mol Genet Metab 1999; 66: 277-82.
7. Haskell RE, Carr CJ, Pearce DA, Bennett MJ, Davidson BL. Batten disease: evaluation of CLN3 mutations on protein localization and function. Hum Mol Genet 2000; 9: 735-44.
8. International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease. Cell 1995; 82: 949-57.
9. Jarvela I, Lehtovirta M, Tikkanen R, Kyttala A, Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet 1999; 8: 1091-8.
10. Joyner AL. Gene targetting: a practical approach. 2nd ed. New York: Oxford University Press; 2001.
11. Katz ML, Gao CL, Prabhakaram M, Shibuya H, Liu PC, Johnson GS. Immunochemical localization of the Batten disease (CLN3) protein in retina. Invest Ophthalmol Vis Sci 1997; 38: 2375-86.
12. Kida E, Kaczmarski W, Golabek AA, Kaczmarski A, Michalewski MP, Wisniewski KE. Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro. Mol Genet Metab 1999; 66: 265-71.
13. Lee RL, Johnson KR, Lerner TJ. Isolation and chromosomal mapping of a mouse homolog of the Batten disease gene CLN3. Genomics 1996; 35: 617-9.
14. Loftus BJ, Kim UJ, Sneddon VP, Kalush F, Brandon R, Fuhrmann J, et al. Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q. Genomics 1999; 60: 295-308.
15. Luiro K, Kopra O, Lehtovirta M, Jalanko A. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum Mol Genet 2001; 10: 2123-31.
16. Margraf LR, Boriack RL, Routheut AA, Cuppen I, Alhilala L, Bennett CJ, et al. Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol Genet Metab 1999; 66: 283-9.
17. Messer A, Plummer J, Maskin P, Coffin JM, Frankel WN. Mapping of the motor neuron degeneration (Mnd) gene, a mouse model of amyotrophic lateral sclerosis (ALS). Genomics 1992; 13: 797-802.
18. Michalewski MP, Kaczmarski W, Golabek AA, Kida E, Kaczmarski A, Wisniewski KE. Posttranslational modification of CLN3 protein and its possible functional implication. Mol Genet Metab 1999; 66: 272-6.
19. Mitchison HM, Munroe PB, O'Rawe AM, Taschner PEM, de Vos N, Kremmidiotis G, et al. Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3. Genomics 1997; 40: 346-50.
20. Mitchison HM, Bernard DJ, Greene NDE, Cooper JD, Junaid MA, Pullarkat RK. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. Neurobiol Dis 1999; 6: 321-34.
21. Munroe PB, Mitchison HM, O'Rawe AM, Anderson JW, Boustany RM, Lerner TJ, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet 1997; 61: 310-6.
22. Oswald MJ, Palmer DN, Damak S. Splicing variants in sheep CLN3, the gene underlying juvenile neuronal ceroid lipofuscinosis. Mol Genet Metab 1999; 67: 169-75.
23. Pardo CA, Rabin BA, Palmer DN, Price DL. Accumulation of the adenosine triphosphate synthase subunit C in the mnd mutant mouse. A model for neuronal ceroid lipofuscinosis. Am J Pathol 1994; 144: 829-35.
24. Persaud-Sawin DA, VanDongen A, Boustany RM. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. Hum Mol Genet 2002; 11: 2129-42.
25. Rapola J. Neuronal ceroid lipofuscinosis in childhood. Perspect Pediatr Pathol 1993; 17: 7-44.
26. Santavouri P. Neuronal ceroid lipofuscinosis in childhood. Brain Dev 1988; 10: 80-3.